These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31750897)

  • 1. Net benefit of oral anticoagulants in patients with atrial fibrillation and active cancer: a nationwide cohort study.
    Atterman A; Friberg L; Asplund K; Engdahl J
    Europace; 2020 Jan; 22(1):58-65. PubMed ID: 31750897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Liu CJ; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Lip GYH; Chen SA
    Circulation; 2018 Jul; 138(1):37-47. PubMed ID: 29490992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study.
    Toorop MMA; Chen Q; Tichelaar VYIG; Cannegieter SC; Lijfering WM
    Eur Heart J; 2021 Oct; 42(40):4126-4137. PubMed ID: 34269375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation based on a CHA
    Methavigul K; Chichareon P; Yindeengam A; Krittayaphong R
    BMC Cardiovasc Disord; 2023 Dec; 23(1):623. PubMed ID: 38114960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
    Friberg L; Rosenqvist M; Lip GY
    Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database.
    Truong B; Hornsby L; Fox B; Chou C; Zheng J; Qian J
    J Thromb Thrombolysis; 2024 Apr; 57(4):638-649. PubMed ID: 38504063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis.
    Kuno T; Takagi H; Ando T; Sugiyama T; Miyashita S; Valentin N; Shimada YJ; Kodaira M; Numasawa Y; Briasoulis A; Burger A; Bangalore S
    J Am Coll Cardiol; 2020 Jan; 75(3):273-285. PubMed ID: 31976865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation.
    Chao TF; Chiang CE; Chan YH; Liao JN; Chen TJ; Lip GYH; Chen SA
    Heart Rhythm; 2021 Jun; 18(6):871-877. PubMed ID: 33640447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?
    Hung Y; Chao TF; Liu CJ; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Liao JN; Chung FP; Lin WY; Lin WS; Cheng SM; Chen TJ; Lip GY; Chen SA
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27702803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study.
    Halvorsen S; Smith JA; Söderdahl F; Thuresson M; Solli O; Ulvestad M; Jonasson C
    BMC Prim Care; 2022 Aug; 23(1):214. PubMed ID: 36008778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bidirectional effects of oral anticoagulants on gut microbiota in patients with atrial fibrillation.
    Li W; Li C; Ren C; Zhou S; Cheng H; Chen Y; Han X; Zhong Y; Zhou L; Xie D; Liu H; Xie J
    Front Cell Infect Microbiol; 2023; 13():1038472. PubMed ID: 37033478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alcohol-related hospitalization is associated with increased risk of ischaemic stroke among low-risk patients with atrial fibrillation.
    Al-Khalili F; Benson L; Friberg L
    Europace; 2018 Jan; 20(1):19-24. PubMed ID: 28339885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
    Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
    Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? A nationwide cohort study.
    Chao TF; Chan YH; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
    Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):588-595. PubMed ID: 34302335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation.
    Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
    Clin Res Cardiol; 2022 Jan; 111(1):23-33. PubMed ID: 33704551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.